JP2015143283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015143283A5 JP2015143283A5 JP2015098562A JP2015098562A JP2015143283A5 JP 2015143283 A5 JP2015143283 A5 JP 2015143283A5 JP 2015098562 A JP2015098562 A JP 2015098562A JP 2015098562 A JP2015098562 A JP 2015098562A JP 2015143283 A5 JP2015143283 A5 JP 2015143283A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- ring
- hydrogen bond
- aromatic ring
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102100030550 Menin Human genes 0.000 claims 1
- 101710169972 Menin Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24010209P | 2009-09-04 | 2009-09-04 | |
| US61/240,102 | 2009-09-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Division JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015143283A JP2015143283A (ja) | 2015-08-06 |
| JP2015143283A5 true JP2015143283A5 (enExample) | 2015-09-17 |
Family
ID=43649670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Active JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
| JP2015098562A Pending JP2015143283A (ja) | 2009-09-04 | 2015-05-13 | 白血病を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Active JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8993552B2 (enExample) |
| EP (1) | EP2473054B1 (enExample) |
| JP (2) | JP5792171B2 (enExample) |
| CN (1) | CN102984941B (enExample) |
| AU (2) | AU2010289321A1 (enExample) |
| CA (1) | CA2773131C (enExample) |
| WO (1) | WO2011029054A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| HRP20161669T1 (hr) | 2009-09-03 | 2017-02-24 | Bristol-Myers Squibb Company | Kinolini kao inhbitori kalijevih ionskih kanala |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| WO2013068592A1 (en) * | 2011-11-10 | 2013-05-16 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| AU2013207972B2 (en) * | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| WO2013112706A1 (en) * | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| EP2671575A1 (en) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
| MY169219A (en) | 2012-06-11 | 2019-03-19 | Bristol Myers Squibb Co | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 ? sulfonamide |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| JP2015528801A (ja) | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| MX2015002887A (es) * | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
| CA2886495C (en) * | 2012-09-28 | 2023-09-19 | Ignyta, Inc. | Azaquinazoline inhibitors of atypical protein kinase c |
| GB201217704D0 (en) * | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| US20140136295A1 (en) | 2012-11-13 | 2014-05-15 | Apptio, Inc. | Dynamic recommendations taken over time for reservations of information technology resources |
| JP2016505012A (ja) | 2013-01-10 | 2016-02-18 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| EP2956470A4 (en) * | 2013-02-15 | 2016-12-07 | Univ Michigan Regents | COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS |
| JP2016512514A (ja) | 2013-03-13 | 2016-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
| CN104119343A (zh) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-三氟甲基噻二唑类化合物及其用途 |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| TWI648281B (zh) * | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| MX2016011675A (es) * | 2014-03-11 | 2016-12-14 | Godavari Biorefineries Ltd | Compuestos dirigidos a las celulas madre de cancer. |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016081732A1 (en) * | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| CN104592248A (zh) * | 2014-12-31 | 2015-05-06 | 芜湖杨燕制药有限公司 | 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法 |
| AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| SG11201807982UA (en) * | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| SG11201809714TA (en) | 2016-05-02 | 2018-11-29 | Univ Michigan Regents | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| HUE053907T2 (hu) | 2016-09-14 | 2021-07-28 | Janssen Pharmaceutica Nv | A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai |
| EP3512858B1 (en) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Fused bicyclic inhibitors of menin-mll interaction |
| EA201990699A1 (ru) | 2016-10-05 | 2019-09-30 | Янссен Фармацевтика Нв | Спиробициклические ингибиторы взаимодействия менин–mll |
| SG11201903483VA (en) | 2016-10-28 | 2019-05-30 | Icahn School Med Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| KR102513564B1 (ko) * | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| JP2020515571A (ja) | 2017-03-31 | 2020-05-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 共有結合性メニン阻害剤としてのピペリジン |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP2021515013A (ja) | 2018-03-06 | 2021-06-17 | アイカーン スクール オブ メディスン アット マウント シナイ | セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法 |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| EP3810145A4 (en) | 2018-06-21 | 2022-06-01 | Icahn School of Medicine at Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| BR112021006273A2 (pt) | 2018-10-03 | 2021-07-06 | Agios Pharmaceuticals Inc | inibidores de menin de pequenas moléculas |
| CN118908962A (zh) | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| WO2021063346A1 (zh) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| WO2022086937A1 (en) * | 2020-10-21 | 2022-04-28 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of enl |
| JP2024518434A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| WO2022237627A1 (en) | 2021-05-08 | 2022-11-17 | Janssen Pharmaceutica Nv | Substituted spiro derivatives |
| US20230250096A1 (en) | 2021-06-01 | 2023-08-10 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES |
| EP4347600A1 (en) | 2021-06-03 | 2024-04-10 | JANSSEN Pharmaceutica NV | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| KR20240021808A (ko) | 2021-06-17 | 2024-02-19 | 얀센 파마슈티카 엔브이 | 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| JP2025538876A (ja) | 2022-11-24 | 2025-12-02 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP4310109B2 (ja) | 2001-04-26 | 2009-08-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物 |
| CN101100472A (zh) | 2001-04-30 | 2008-01-09 | 美国拜尔公司 | 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用 |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2004030672A1 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| CA2535265C (en) * | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| WO2006014420A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| JP2009507004A (ja) * | 2005-09-02 | 2009-02-19 | テイボテク・フアーマシユーチカルズ・リミテツド | Ｈｃｖ阻害剤としてのベンゾジアゼピン |
| CN101466716A (zh) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| WO2008099019A1 (en) * | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| JP5284291B2 (ja) * | 2007-03-19 | 2013-09-11 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 潜在的制癌剤としての新規アントラニル酸誘導体及びその調製方法 |
| JP2010530736A (ja) * | 2007-05-25 | 2010-09-16 | バーンハム インスティトゥート フォー メディカル リサーチ | タプシガルジンにより誘導される細胞死の阻害剤 |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009064388A2 (en) * | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
| US20100063047A1 (en) | 2008-09-10 | 2010-03-11 | Kalypsys, Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| BR112012000422A2 (pt) * | 2009-07-08 | 2017-05-09 | Leo Pharma As | composto, composição farmacêutica, uso de um composto, e, método para a prevenir tratar ou melhorar doenças do sistema imune |
-
2010
- 2010-09-03 WO PCT/US2010/047894 patent/WO2011029054A1/en not_active Ceased
- 2010-09-03 JP JP2012528106A patent/JP5792171B2/ja active Active
- 2010-09-03 CN CN201080050708.8A patent/CN102984941B/zh active Active
- 2010-09-03 EP EP10814591.3A patent/EP2473054B1/en active Active
- 2010-09-03 US US12/875,968 patent/US8993552B2/en active Active
- 2010-09-03 AU AU2010289321A patent/AU2010289321A1/en not_active Abandoned
- 2010-09-03 CA CA2773131A patent/CA2773131C/en active Active
-
2014
- 2014-06-27 AU AU2014203516A patent/AU2014203516B2/en active Active
-
2015
- 2015-03-23 US US14/665,600 patent/US20160045504A1/en not_active Abandoned
- 2015-05-13 JP JP2015098562A patent/JP2015143283A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015143283A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| JP2016540742A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2010504286A5 (enExample) | ||
| PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
| JP2018511647A5 (enExample) | ||
| JP2016537382A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| JP2013510178A5 (enExample) | ||
| JP2014513051A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| JP2014526533A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| RU2016118399A (ru) | Производные 4-аминометилбензойной кислоты | |
| JP2014510147A5 (enExample) | ||
| JP2015063518A5 (ja) | 有機化合物 | |
| JP2015500842A5 (enExample) | ||
| CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 |